News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
739,477 Results
Type
Article (42545)
Company Profile (233)
Press Release (696689)
Multimedia
Podcasts (109)
Webinars (22)
Section
Business (206253)
Career Advice (2050)
Deals (35821)
Drug Delivery (140)
Drug Development (82201)
Employer Resources (174)
FDA (16740)
Job Trends (15123)
News (349720)
Policy (33556)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2638)
Accelerated approval (55)
ADA (44)
Adcomms (32)
Allergies (195)
Alliances (50012)
ALS (229)
Alzheimer's disease (1848)
Antibody-drug conjugate (ADC) (534)
Approvals (17214)
Artificial intelligence (735)
ASCO (333)
Autoimmune disease (350)
Automation (63)
Bankruptcy (364)
Best Places to Work (11687)
BIO (66)
BIOSECURE Act (20)
Biosimilars (239)
Biotechnology (149)
Bladder cancer (205)
Brain cancer (78)
Breast cancer (816)
Cancer (6381)
Cardiovascular disease (511)
Career advice (1748)
Career pathing (45)
CAR-T (357)
CDC (59)
Celiac Disease (3)
Cell therapy (971)
Cervical cancer (57)
Clinical research (71994)
Collaboration (2215)
Commercialization (1)
Company closure (5)
Compensation (1493)
Complete response letters (88)
COVID-19 (2811)
CRISPR (118)
C-suite (1247)
Cystic fibrosis (156)
Data (8667)
Decentralized trials (3)
Denatured (30)
Depression (176)
Dermatology (98)
Diabetes (669)
Diagnostics (7052)
Digital health (64)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (368)
Drug pricing (221)
Drug shortages (31)
Duchenne muscular dystrophy (310)
Earnings (92647)
Editorial (70)
Employer branding (22)
Employer resources (156)
Events (121296)
Executive appointments (1135)
FDA (20782)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (35)
Funding (1863)
Gene editing (249)
Generative AI (62)
Gene therapy (754)
GLP-1 (1115)
Government (5078)
Grass and pollen (7)
Guidances (421)
Healthcare (19313)
Hematology (192)
HIV (92)
Huntington's disease (62)
IgA nephropathy (111)
Immunology and inflammation (304)
Immuno-oncology (107)
Indications (222)
Infectious disease (3179)
Inflammatory bowel disease (224)
Inflation Reduction Act (15)
Influenza (142)
Intellectual property (320)
Interviews (323)
IPO (16729)
IRA (54)
Job creations (3723)
Job search strategy (1446)
JPM (59)
Kidney cancer (21)
Labor market (112)
Layoffs (583)
Leadership (43)
Legal (8104)
Liver cancer (107)
Longevity (35)
Lung cancer (855)
Lymphoma (479)
Machine learning (66)
Management (61)
Manufacturing (1162)
Marketing (4)
MASH (208)
Medical affairs (1)
Medical device (14066)
Medtech (14239)
Mergers & acquisitions (20407)
Metabolic disorders (1667)
mRNA (228)
Multiple sclerosis (200)
NASH (17)
Neurodegenerative disease (458)
Neuropsychiatric disorders (109)
Neuroscience (3493)
Neurotech (1)
NextGen: Class of 2026 (6557)
Non-profit (4585)
Now hiring (82)
Obesity (771)
Opinion (304)
Ovarian cancer (241)
Pain (268)
Pancreatic cancer (353)
Parkinson's disease (396)
Partnered (36)
Patents (647)
Patient recruitment (770)
Peanut (68)
People (60293)
Pharmaceutical (55)
Pharmacy benefit managers (34)
Phase 1 (22403)
Phase 2 (31667)
Phase 3 (23672)
Pipeline (9886)
Policy (343)
Postmarket research (2615)
Preclinical (9514)
Press Release (65)
Prostate cancer (338)
Psychedelics (59)
Radiopharmaceuticals (351)
Rare diseases (1188)
Real estate (6025)
Recruiting (72)
Regulatory (26234)
Reports (56)
Research institute (2442)
Resumes & cover letters (354)
Rett syndrome (46)
RNA editing (25)
RSV (92)
Schizophrenia (183)
Series A (315)
Series B (235)
Service/supplier (12)
Sickle cell disease (120)
Special edition (26)
Spinal muscular atrophy (170)
Sponsored (48)
Startups (3672)
State (2)
Stomach cancer (19)
Supply chain (136)
Tariffs (93)
The Weekly (77)
Vaccines (1170)
Venture capital (121)
Weight loss (496)
Women's health (138)
Worklife (21)
Date
Today (111)
Last 7 days (506)
Last 30 days (2420)
Last 365 days (30465)
2026 (16327)
2025 (30290)
2024 (35336)
2023 (40222)
2022 (51370)
2021 (55967)
2020 (54413)
2019 (46970)
2018 (35354)
2017 (32333)
2016 (31768)
2015 (37790)
2014 (31589)
2013 (26580)
2012 (28784)
2011 (29472)
2010 (27550)
Location
Africa (763)
Alabama (93)
Alaska (7)
Arizona (367)
Arkansas (14)
Asia (40298)
Australia (6617)
California (14024)
Canada (4013)
China (1500)
Colorado (597)
Connecticut (614)
Delaware (436)
Europe (87653)
Florida (2120)
Georgia (448)
Hawaii (3)
Idaho (64)
Illinois (1154)
India (100)
Indiana (633)
Iowa (25)
Japan (601)
Kansas (133)
Kentucky (51)
Louisiana (58)
Maine (76)
Maryland (1663)
Massachusetts (10054)
Michigan (377)
Minnesota (759)
Mississippi (6)
Missouri (157)
Montana (33)
Nebraska (30)
Nevada (149)
New Hampshire (85)
New Jersey (3677)
New Mexico (30)
New York (3685)
North Carolina (1765)
North Dakota (9)
Northern California (7092)
Ohio (420)
Oklahoma (23)
Oregon (41)
Pennsylvania (2792)
Puerto Rico (31)
Rhode Island (52)
South America (1128)
South Carolina (87)
South Dakota (2)
Southern California (5561)
Tennessee (232)
Texas (2252)
United States (49497)
Utah (417)
Vermont (2)
Virginia (345)
Washington D.C. (81)
Washington State (1117)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
739,477 Results for "astrazeneca canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Breast cancer
AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote
An FDA advisory committee recently voted against approving AstraZeneca’s oral SERD drug camizestrant for certain patients with advanced breast cancer. It is unclear when the new target action date for the drug will be.
May 27, 2026
·
4 min read
·
Tristan Manalac
Earnings
AstraZeneca bullish on $80B sales goal after beating expectations, Phase 3 data wins
After a quarter in which sales topped $15 billion and key readouts went AstraZeneca’s way, the company is increasingly confident that its 2030 revenue target is in reach.
April 29, 2026
·
2 min read
·
Nick Paul Taylor
Weight loss
ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data
AstraZeneca is pushing its small molecule GLP-1 drug to Phase 3 development for weight control, diabetes and other cardiometabolic conditions despite the asset failing to best one from Structure Therapeutics.
June 9, 2026
·
1 min read
·
Tristan Manalac
Pipeline
AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio
While AstraZeneca has discontinued work on four assets—including one in asthma and another in acromegaly—the pharma has also elected to take forward a bispecific antibody that destroys the EGFR protein.
April 30, 2026
·
2 min read
·
Tristan Manalac
Approvals
AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs
Baxfendy, the first aldosterone synthase inhibitor to be approved by the FDA for high blood pressure, is among the products AstraZeneca is relying on to hit its 2030 goal of $80 billion in revenue.
May 18, 2026
·
1 min read
·
Tristan Manalac
Adcomms
AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions
In briefing documents released Wednesday, the FDA raises doubts about two AstraZeneca assets set to be discussed Friday at the agency’s first drug-related advisory committee meeting in nine months.
April 29, 2026
·
3 min read
·
Tristan Manalac
Adcomms
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
The FDA’s cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT inhibitor Truqap in prostate cancer.
March 9, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro® (dorocubicel) Securing Canadian rights to a proprietary advanced clinical-stage product candidate developed in Canada adds to Medexus’s medium-term product pipeline and helps build a North American allo-HSCT franchise
June 10, 2026
·
16 min read
Lung cancer
AstraZeneca’s ATR Inhibitor Fails To Improve Survival in Phase III Lung Cancer Trial
Ceralasertib is part of AstraZeneca’s ambitious plan to hit $80 billion in revenue by 2030.
December 22, 2025
·
1 min read
·
Annalee Armstrong
Business
JPM26: AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Launches
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs for hypertension, breast cancer and generalized myasthenia gravis, all of which are currently under FDA review.
January 14, 2026
·
2 min read
·
Tristan Manalac
1 of 73,948
Next
